Speqta: Strategic Review Completed
Redeye retains its positive view on Speqta following the Strategic Review. We believe the significant cash dividend combined with investments in Bidbrain is a balanced low-risk approach that should satisfy most shareholders.
Sign up for free to continue
Already a member?
Disclosures and disclaimers
Premium Plan required to unlock